Home | epochnews Logo

Category Headlines 
 
 News of Interest
 
 M & A
 Financial Sponsor
 Fund and Fund
 Fund and Public
 Public and Private
 Private and Private
 Public and Public
 Catalyst, Rumor, Ideas
 Trends/Research
 
 Financing
 North America
 Europe
 Asia
 
 Fund News
 Venture
 Buyout/Corp. Restructuring
 Expansion Capital
 Energy/Natural Resources
 Distressed
 Turnarounds
 International
 Special Situations
 FOF
 
 Name/Address Change
 Portfolio Company
 
 IPOs
 Pricing
 Filings
 Withdrawn
 
 Staff Changes
 GP Staff
 LP Staff
 Director/Officer
 Other
 
 Real Estate
 
 Conference
 
 Bankruptcy
 
 Hedge Funds
 
 Earnings
 
 Legal Actions
 
 Bad News
 
 MBA Programs
 
 Vacation Hot Spots
Search

Financing : Asia Last Updated: Jul 13th, 2006 - 10:20:17


Dr. Reddy's and ICICI Venture Announce USD 56 Million-Partnership

Location: Hyderabad & Mumbai, India
Date: Mar 27, 2005

Email this article
 Printer friendly page

Dr. Reddy's Laboratories (RDY) announced today that the Company has entered into a USD 56 million agreement with ICICI Venture Funds Management Company for the development and commercialization of ANDAs to be filed in 2004-05 and 2005-06.

Under the terms of the agreement, ICICI Venture will fund the development, registration and legal costs related to the commercialization of ANDAs on a pre-determined basis. This agreement covers most of the ANDAs to be filed by Dr. Reddy's during the years 2004-05 and 2005-06. On commercialization of these products, Dr. Reddy's will pay ICICI Venture royalty on net sales for a period of 5 years. The specific financial terms of the agreement have not been disclosed.

Under the terms of the agreement, ICICI Venture will fund USD 22.5 million dollars in the first phase with an option to invest an additional USD 33.5 million dollars in the second phase.




INFO SOURCES

Dr. Reddy's Laboratories (RDY)

FIRMS

Established in 1984, Dr. Reddy's Laboratories (RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.  

ICICI Venture, incorporated in 1988, as a wholly owned subsidiary of ICICI Bank, is the most experienced and largest private equity and venture fund management company in India with funds currently under management in excess of Rs.20 billion (USD 400 million). Over the last 15 years, ICICI Venture has been successful in identifying trends well ahead of the curve; be it retail, media and entertainment, information technology, real estate or pharmaceuticals and biotechnology. During this period ICICI Venture launched and managed 8 funds with a corpus exceeding Rs. 20 billion (USD 400 million). Each fund had a distinct investment theme and ICICI Venture today has some of the best known and managed companies in India in its portfolio.

 


Supporting Material


© Copyright by PEsource

Top of Page

Asia
Latest Headlines
Alticast Closes $21 Million in New Financing
Little Sheep Raises $25 Million
IDB Infrastructure Fund L.P. Invests in Globeleq
Kantana Group Announces Investment by Lombard
MobiApps Raises $ 10 Million Series B
ECONZ Raises $3 Million
Cellon International Raises Series D Round
Bharti Telesoft Raises $13.5 Million
Goldsun Raises $1.55 Million from Mekong Capital
SpineVision Raises $16+ Million -- FlexSpine Launched
Times Internet Raises $7 Million from WestBridge Capital Partners
OPTWARE $14 Million in Series 5 Financing
InterCure Raises $3 Million in First Closing of Series C Round
Dr. Reddy's and ICICI Venture Announce USD 56 Million-Partnership
Xeround Systems Raises $ 6.5M Round